Orexigen Therapeutics (OREX) Misses Q2 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016
August 4, 2016 4:01 PM EDTSAN DIEGO, Aug. 4, 2016 /PRNewswire/ --Â Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the second quarter ended June 30, 2016.
"Earlier this week we completed our acquisition of U.S. rights to Contrave®, transforming Orexigen into a fully integrated commercial pharmaceutical company focused on our mission to improve the health and lives of patients struggling to lose weight," said Mike Narachi, CEO of Orexigen. "With the completion of this acquisition and the development of our independent commercialization capabilities over the past several months,... More
